Overview

Treatment of Pancreatic Cancer With Abraxane

Status:
Completed
Trial end date:
2020-09-07
Target enrollment:
Participant gender:
Summary
This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine. Additionally data on dosage that is actually used in these patients will be collected. Patients who have pancreatic cancer and additional diseases can be documented in this study, too. Collected data might generate learnings on the optimal use of Abraxane in the daily routine setting.
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel